Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together leaders in the field of translational mitochondrial medicine, with a programme designed to engage and inspire the next generation of mitochondrial researchers. Read more about the event.
Find more articles
- Khondrion receives EMA agreement on its Paediatric Investigation Plan for sonlicromanol
- Khondrion announces publication in Scientific Reports outlining an additional anti-inflammatory mode of action for its lead phase IIb-stage drug candidate sonlicromanol
- 2020 – A Year in Review
- Khondrion joins Consortium researching metabolomic processes to predict and prevent COVID-19
- Interview with Herma Renkema, Chief Early Development Officer at Khondrion
- Khondrion shares progress of sonlicromanol development programme at Mitochondrial Medicine 2020 virtual conference
- Disease spotlight: Maternally inherited diabetes and deafness
- Khondrion to present at Mitocon’s 10th Italian Meeting on Mitochondrial Diseases
- Khondrion announces new Scientific Advisory Board
- Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
- Mitochondrial disease heterogeneity: Studying a disease with many faces
- Disease spotlight: Leigh disease
- Q&A with Rob van Maanen
- Khondrion appoints Herma Renkema as Chief Early Development Officer
- Disease spotlight: Cognition and mitochondrial disease
- Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease
- MELAS Syndrome
- Khondrion appoints Rob van Maanen as Chief Medical Officer
- Interview with Julien Beyrath, Chief Scientific Officer at Khondrion
- Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases
- Khondrion becomes partner in DuSRA-VOILA collaboration
- CEO Jan Smeitink on Khondrion’s development program and plans for 2020
- Reflections on the Mitochondrial Medicine 2019 Conference
- Khondrion strengthens executive team with COO Arnout Ploos van Amstel
- Mitochondrial Medicine 2019